Drug Safety Problems Show Potential For Follow-On Biologics, Jaeger Says
This article was originally published in The Pink Sheet Daily
Executive Summary
GPhA President Jaeger argues that improved analytics developed in the wake of the heparin problems suggest that non-clinical verification of follow-on products is possible.
You may also be interested in...
Greenwood In The “Wolves’ Den”: BIO CEO Visits GPhA
His address to the generic association’s annual meeting is cordial, but “consensus is difficult,” on follow-on biologics, Greenwood says. “We just may have an amendment battle and count the votes.”
Greenwood In The “Wolves’ Den”: BIO CEO Visits GPhA
His address to the generic association’s annual meeting is cordial, but “consensus is difficult,” on follow-on biologics, Greenwood says. “We just may have an amendment battle and count the votes.”
Earnings Healthy, Genzyme’s Bigger-Batch Myozome Plant On Track For Approval
2,000-liter version of Pompe therapy, rebranded as Lumizyme, due for action later this month.